Humanized anti CXCR4 antibodies for the treatment of cancer
US9249223B2 · kind B2 · utility
3Cited by
11References
21Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Mar 30, 2011 |
| Grant date | Feb 2, 2016 |
| Priority date | — |
| Expiry date | Mar 30, 2031 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/76
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to a novel isolated humanized antibody, or the derived compounds or functional fragments of same, capable of binding to CXCR4 but also of inducing conformational changed of the CXCR4 homodimers and/or heterodimers. More particularly, the present invention relates to hz515H7 antibodies, specific to the CXCR4 protein, as well as their use for the treatment of cancer. Pharmaceutical compositions composed of such antibodies and a process for the selection of such antibodies are also covered.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.